FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual MeetingPRNewsWire · 5 days ago
FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal DiscsPRNewsWire · Oct 14, 2026
FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the BodyPRNewsWire · Oct 7, 2026
FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic ActivityPRNewsWire · Sep 29, 2026
FibroBiologics, Inc. (FBLG) Discusses Strategy and Clinical Progress in Fibroblast-Based Cell Therapies for Chronic Diseases TranscriptSeeking Alpha · Sep 22, 2026
FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific OfficerPRNewsWire · Sep 17, 2026FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 31, 2026 | -$0.93 | -$0.66 | Beat |
| Apr 30, 2026 | -$1.26 | -$1.33 | Miss |
| Feb 24, 2026 | -$1.44 | -$0.98 | Beat |
| Oct 31, 2025 | -$2.00 | -$2.60 | Miss |
| Jul 31, 2025 | -$0.11 | -$2.40 | Miss |
| May 14, 2025 | -$2.00 | -$2.80 | Miss |